Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

被引：2
|
作者：
Davies, Andrew J. [1 ,2 ]
Caddy, Josh [3 ]
McLaughlin, Katy [3 ]
Wignall, Christopher [3 ]
Waugh, Robert [3 ]
Collins, Graham P. [4 ]
Stanton, Louise [3 ]
Saunders, Geoff N. [3 ]
Cummin, Thomas [5 ]
Schuh, Anna [6 ]
Ardeshna, Kirit M. [7 ]
McMillan, Andrew K. [8 ]
Radford, John [9 ,10 ]
Lewis, David John [11 ]
Coleman, Adam R. [1 ]
Griffiths, Gareth [3 ]
Burton, Cathy [12 ]
Barrans, Sharon [12 ]
Johnson, Peter [1 ,13 ]
机构：
[1] Canc Res UK Expt Canc Med Ctr UK, Southampton, Hants, England
[2] Southampton Canc Res UK Ctr, Southampton, Hants, England
[3] Univ Southampton, Canc Res UK Southampton Clin Trials Unit, Southampton, Hants, England
[4] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England
[5] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England
[6] Univ Oxford, Oxford Mol Diagnost Ctr, Oxford, England
[7] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England
[8] Nottingham Univ Hosp NHS Trust, Nottingham, England
[9] Univ Manchester, NIHR Clin Res Facil, Manchester, Lancs, England
[10] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[11] Derriford Hosp, Dept Haematol, Plymouth, Devon, England
[12] Leeds Canc Ctr, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England
[13] Univ Southampton, Fac Med, Sch Canc Sci, Southampton, Hants, England
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163499
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9478 / 9479
页数：2
相关论文
共 50 条
  • [21] Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
    Friedberg, Jonathan W.
    Thompson, Carrie A.
    Trneny, Marek
    Morschhauser, Franck
    Salles, Gilles
    Reagan, Patrick M.
    Hertzberg, Mark
    Smolewski, Piotr
    Zhang, Huilai
    Thieblemont, Catherine
    Hu, Bei
    Fonseca, Gustavo
    Kim, Won-Seog
    Martelli, Maurizio
    Mehta, Amitkumar
    Campinha-Bacote, Avrita
    Yan, Mark
    Hirata, Jamie
    Sugidono, Matthew
    Lee, Calvin
    Sharman, Jeff P.
    BLOOD, 2022, 140 : 6623 - 6626
  • [22] Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy
    Shanavas, Mohamed
    Law, Soi-Cheng
    Hertzberg, Mark
    Hicks, Rodney J.
    Seymour, John F.
    Li, Zhixiu
    Merida de Long, Lilia
    Nath, Karthik
    Sabdia, Muhammed B.
    Gunawardana, Jay
    Gandhi, Maher K.
    Keane, Colm
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (11)
  • [23] Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
    Song, Guoqi
    Ni, Huiyun
    Zou, Linqing
    Wang, Shukui
    Tian, Fuliang
    Liu, Hong
    Cho, William C.
    ONCOTARGETS AND THERAPY, 2016, 9 : 3799 - 3805
  • [24] Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL)
    Shah, Nirav Niranjan
    Szabo, Aniko
    Rajguru, Saurabh
    Devata, Sumana
    Howard, Mitch
    Pereira, Deepa
    Endres, Mariah
    Longo, Walter L.
    Hamadani, Mehdi
    Fenske, Timothy S.
    Fletcher, Christopher David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Phase II study of the tetrahydropyranyl adriamycin--cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma
    Kasahara, Senji
    Hara, Takeshi
    Tsurumi, Hisashi
    Goto, Naoe
    Kitagawa, Jun-Ichi
    Kanemura, Nobuhiro
    Yoshikawa, Takeshi
    Goto, Hideko
    Fukuno, Kenji
    Yamada, Toshiki
    Sawada, Michio
    Takahashi, Takeshi
    Takami, Tsuyoshi
    Moriwaki, Hisataka
    LEUKEMIA & LYMPHOMA, 2011, 52 (04) : 629 - 634
  • [26] A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma
    Tsurumi, Hisashi
    Hara, Takeshi
    Goto, Naoe
    Kitagawa, Jun-Ichi
    Kanemura, Nobuhiro
    Yoshikawa, Takeshi
    Kasahara, Senji
    Goto, Hideko
    Fukuno, Kenji
    Yamada, Toshiki
    Sawada, Michio
    Shimizu, Masahito
    Takahashi, Takeshi
    Takami, Tsuyoshi
    Moriwaki, Hisataka
    LEUKEMIA & LYMPHOMA, 2012, 53 (02) : 247 - 253
  • [27] Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL)
    Younes, Anas
    Flinn, Ian
    Berdeja, Jesus G.
    Friedberg, Jonathan W.
    Alberti, Sara
    Thieblemont, Catherine
    Morschhauser, Franck
    Hellemans, Peter
    Hall, Brett
    Smit, Johan
    Skee, Donna
    de Vries, Ronald
    Todorovic, Marija
    Khan, Imran
    Fourneau, Nele
    Oki, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515
    Stopeck, Alison T.
    Unger, Joseph M.
    Rimsza, Lisa M.
    Farnsworth, Brent
    LeBlanc, Michael
    Iannone, Maria
    Fisher, Richard I.
    Miller, Thomas P.
    BLOOD, 2010, 116 (21) : 260 - 261
  • [29] Rituximab in Combination with Cyclophosphamide, Mitoxantrone, Vincristine and Prednisone (R-CNOP) As First Line Regimen in Elderly Patients with Diffuse Large B-Cell Lymphoma
    Aslan, Alma
    Turker, Alev
    Kars, Ayse
    Barista, Ibrahim
    Ozdemir, Evren
    BLOOD, 2016, 128 (22)
  • [30] A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) us subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL)
    Younes, Anas
    Zinzani, Pier Luigi
    Sehn, Laurie Helen
    Johnson, Peter W. M.
    Gascoyne, Randy D.
    Ahmedi, Tahamtan
    Bellew, Kevin M.
    Verrneulen, Jessica
    Zhuang, Sen Hong
    Sun, Stevan
    Staudt, Louis M.
    Wilson, Wyndham Hopkins
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345